calcitriol and Ovarian-Neoplasms

calcitriol has been researched along with Ovarian-Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for calcitriol and Ovarian-Neoplasms

ArticleYear
1α,25‑Dihydroxyvitamin D3 restrains stem cell‑like properties of ovarian cancer cells by enhancing vitamin D receptor and suppressing CD44.
    Oncology reports, 2019, Volume: 41, Issue:6

    Scientific evidence linking vitamin D with various cancer types is growing, but the effects of vitamin D on ovarian cancer stem cell‑like cells (CSCs) are largely unknown. The present study aimed to examine whether vitamin D was able to restrain the stemness of ovarian cancer. A side population (SP) from malignant ovarian surface epithelial cells was identified as CSCs, in vitro and in vivo. Furthermore, 1α,25‑dihydroxyvitamin D3 [1α,25(OH)2D3] treatment inhibited the self‑renewal capacity of SP cells by decreasing the sphere formation rate and by suppressing the mRNA expression levels of cluster of differentiation CD44, NANOG, OCT4, SOX2, Krüppel‑like factor 4 and adenosine triphosphate binding cassette subfamily G member 2. Additionally, 1α,25(OH)2D3 treatment decreased the expression of Cyclin D1, whereas it increased the expression of β‑catenin and vitamin D receptor (VDR). Notably, immunofluorescence staining verified that 1α,25(OH)2D3 promoted the expression of β‑catenin in the cytoplasm. Furthermore, vitamin D3 delayed the onset of tumor formation derived from injection of ovarian CSCs to nude mice, by reducing CD44 and enhancing β‑catenin expressions in vivo. In conclusion, 1α,25(OH)2D3 restrains the stem cell‑like properties of ovarian cancer cells by enhancing the expression of VDR, by promoting the expression of β‑catenin in the cytoplasm, and by suppressing the expression of CD44. These findings provide a novel insight into the functions of vitamin D in diminishing the stemness of cancer CSCs.

    Topics: beta Catenin; Cell Self Renewal; Female; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Nanog Homeobox Protein; Neoplastic Stem Cells; Octamer Transcription Factor-3; Ovarian Neoplasms; Receptors, Calcitriol; SOXB1 Transcription Factors; Vitamin D

2019
RIPK1 binds to vitamin D receptor and decreases vitamin D-induced growth suppression.
    The Journal of steroid biochemistry and molecular biology, 2017, Volume: 173

    Receptor interacting protein kinase 1 (RIPK1) is an enzyme acting downstream of tumor necrosis factor alpha to control cell survival and death. RIPK1 expression has been reported to cause drug resistance in cancer cells, but so far, no published studies have investigated the role of RIPK1 in vitamin D signaling. In the present study, we investigated whether RIPK1 plays any roles in 1,25-dihydroxyvitamin D3 (1,25D3)-induced growth suppression. In our studies, RIPK1 decreased the transcriptional activity of vitamin D receptor (VDR) in luciferase reporter assays independent of its kinase activity, suggesting a negative role of RIPK1 in 1,25D3 action. RIPK1 also formed a complex with VDR, and deletion analyses mapped the RIPK1 binding region to the C-terminal ligand-binding domain of the VDR. Subcellular fractionation analyses indicated that RIPK1 increased VDR retention in the cytoplasm, which may account for its inhibition of VDR transcriptional activity. Consistent with the reporter analyses, 1,25D3-induced growth suppression was more pronounced in RIPK1-null MEFs and RIPK1-knockdown ovarian cancer cells than in control cells. Our studies have defined RIPK1 as a VDR repressor, projecting RIPK1 depletion as a potential strategy to increase the potency of 1,25D3 and its analogs for cancer intervention.

    Topics: Cell Line, Tumor; Cell Proliferation; Cytoplasm; Female; Gene Expression Regulation; Gene Knockdown Techniques; HEK293 Cells; Humans; Ovarian Neoplasms; Protein Binding; Protein Domains; Receptor-Interacting Protein Serine-Threonine Kinases; Receptors, Calcitriol; Vitamin D

2017